All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The Lupus Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lupus Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Ricard CerveraSteering Committee Chair
Ricard Cervera is Head of the Department of Autoimmune Diseases at Hospital Clínic de Barcelona, Barcelona, ES, and Director of the Research Group on Systemic Autoimmune Diseases at Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ES. He is also Director of the UB-GSK Chair on Autoimmune Diseases, Coordinator of the Masters’ on Autoimmune Diseases, and Academic Vice-Dean at the Faculty of Medicine and Health Sciences of the University of Barcelona, Barcelona, ES.
Professor Cervera has authored more than 1,000 articles, with research focusing on systemic lupus erythematosus and the antiphospholipid syndrome, with special focus on its “catastrophic” variant.